Publications

Clear Search

Showing 2 results for “Nintedanib”.

June 2025

EULAR recommendations for the treatment of systemic sclerosis: 2023 update

Ann Rheum Dis 2025;84:29–40 DOI: 10.1136/ard-2024-226430

Del Galdo et al. formed a new task force to update the EULAR recommendations for the pharmacological management of systemic sclerosis (SSc). The task force agreed on 22 new recommendations covering eight clinical/organ domains: Raynaud’s phenomenon (RP), digital ulcers, pulmonary arterial hypertension (PAH), musculoskeletal, skin fibrosis, interstitial lung disease (ILD), gastrointestinal, and renal crisis.

more…

Nintedanib for systemic sclerosis–associated interstitial lung disease

N Engl J Med 2019;380:2518–28 doi: 10.1056/NEJMoa1903076

Distler et al. reported that the annual rate of decline in FVC through Week 52 was lower with nintedanib than with placebo among patients with ILD associated with SSc. No clinical benefit of nintedanib was observed for other manifestations of SSc. The safety profile of nintedanib was similar to that observed in patients with idiopathic pulmonary fibrosis.

more…